本文采用肥大细胞膜稳定剂曲尼司特与免疫增强剂人脾转移因子联合应用防治支气管哮喘52例,总有效率96.1％,与钙通道阻滞剂硝苯吡啶为对照,两组疗效差异显著(P<0.01)。并对治疗组观察了三种不同类型支气管哮喘的疗效比较,效果均较满意,且组间无显著差异(P>0.05)。 In this paper, mast cell membrane stabilizer tranilast and immune enhancers of human spleen transfer factor combined with prevention and treatment of bronchial asthma in 52 cases, the total effective rate was 96.1%, and calcium channel blocker nifedipine as control, the two groups showed significant differences in therapeutic effect P <0.01). The curative effects of three different types of bronchial asthma were observed in the treatment group, the results were satisfactory, and there was no significant difference between the two groups (P> 0.05).